How does NHLBI Support HIV-Related Research?
The NHLBI has a robust portfolio of HIV-related grants that are managed in its three divisions, the Division of Cardiovascular Sciences, the Division of Lung Diseases, and the Division of Blood Diseases and Resources. HIV-related pediatric research is managed within the heart, lung, or blood division most relevant to the research content. The goals, past successes and future interests of the NHLBI AIDS Program are described in the About the AIDS Program section.
HIV-Related Funding Opportunities
The NHLBI AIDS team is pleased to announce the publication of three NHLBI AIDS Funding Opportunity Announcements.
A Notice of Intent to Publish has also been released for
an additional NHLBI AIDS funding opportunity.
How are HIV-related applications reviewed at NHLBI?
Expedited Review of AIDS/HIV-Related Applications:
As mandated by Congress, all AIDS/HIV-related applications receive an expedited advisory Council review that allows the Institute to award qualifying grants one Council earlier than the standard non AIDS/ HIV-related schedule would indicate. To be eligible for expedited review, the application must address research goals that are relevant to AIDS/HIV. For investigator-initiated AIDS applications reviewed in the Center for Scientific Review (CSR), the receipt date is about two months after the standard receipt date for a typical R01 application. For NIH receipt dates and the AIDS review cycle see: http://grants.nih.gov/grants/funding/submissionschedule.htm#AIDS
All NIH grant applications are received by the Division of Receipt and Referral in CSR. If you are submitting an investigator-initiated application that has primary aims focused specifically on HIV-related heart, lung, or blood disease, you may wish to include in your cover letter a request that the application be assigned to NHLBI. The Division of Receipt and Referral will review such requests, but is not obligated to grant them.
Staff members in the Division of Receipt and Referral assign investigator-initiated applications to an Initial Review Group (IRG) within CSR that has the appropriate scientific expertise. The head of the IRG further assigns the application to a study section best suited to review the application, or alternatively, arranges for a Special Emphasis Panel (SEP).
Applications received in response to an NHLBI Request for Applications (RFA) are referred by CSR to the NHLBI Office of Scientific Review (OSR). These applications are assigned to an NHLBI Scientific Review Officer (SRO) to arrange a SEP peer review meeting. Applications submitted in response to a Program Announcement with special receipt, referral and/or review considerations (PAR) can be reviewed by either CSR or the NHLBI OSR. Location of the review venue is stated in the specific PAR announcement.
Investigator-Initiated AIDS/HIV Applications (CSR Review):
Most investigator-initiated AIDS R01 applications are reviewed by the AIDS and Related Research IRG (AARR). The AARR currently consists of nine study sections as well as special emphasis panels. See the following for a list and description: http://public.csr.nih.gov/StudySections/IntegratedReviewGroups/AARRIRG/Pages/default.aspx. The AARR IRG reviews applications in all areas of basic, translational, clinical and behavioral aspects of HIV/AIDS research.
AIDS/HIV Applications in Response to an NHLBI RFA or PAR:
Applications received in response to an NHLBI Request for Applications (RFA) are referred by CSR to the NHLBI Office of Scientific Review (OSR) for review. These applications receive a review by a SEP.
Applications submitted in response to a Program Announcement with special receipt, referral and/or review considerations (PAR) can be reviewed within CSR or the NHLBI OSR. Location of the review venue will be stated within the specific PAR announcement.
Applications must be responsive to the specific requirements of the RFA/PAR and serve the NHLBI mission.
Standing Review Committees Within NHLBI:
The OSR has three standing review committees for investigator-initiated applications. These are the Clinical Trials Review Committee (CLTR), the Heart, Lung, and Blood Program Project Review Committee (HLBP), and the NHLBI Institutional Training Mechanism Review Committee (NITM). Applications received in response to NHLBI's PAR entitled "Investigator Initiated Multi-Site Clinical Trials (Collaborative R01)" are assigned to CLTR for review. Program Project (P01) applications submitted to NHLBI are assigned to HLBP for review. National Research Service Award (NRSA) Institutional Research Training Grants (T32) submitted to NHLBI are assigned to NITM for review. Multi-Site Clinical Trial applications must indicate the specific PAR announcement to ensure assignment to the NHLBI standing review committee.
For further information on review of grant applications by the NHLBI Office of Scientific Review please contact:
Director, Office of Scientific Review
For further information about the process of review for HIV-related heart, lung, and blood applications, please contact:
Tony L. Creazzo, PhD